|
|
|
| Effects of Valsartan Combined with Atorvastatin on hs-CRP, LDL-C and SCr Levels and Kidney Function of Patients with Early Diabetic Nephropathy |
| CHEN Cheng-hua,WANG Li,ZHANG Shou-lai |
| Department of Endocrinology, Rizhao Traditional Chinese Medicine Hospital, Shandong Province, Rizhao, Shandong 276800 |
|
|
|
|
Abstract 【Objective】To discuss effects of valsartan combined with atorvastatin on hs-CRP, LDL-C and SCr levels and kidney function of patients with early diabetic nephropathy.【Methods】From June 2013 to October 2016, 92 patients with DN were randomly divided into observation group and control group with 46 cases in each group. The control group was treated with valsartan alone, the observation group was treated with atorvastatin on the basis of the control group, and the LDL-C levels of hs-CRPN SCr were compared between the two groups before and after treatment. Renal function index and incidence of adverse reactions. The levels of hs-CRP, LDL-C, renal function indexesβ2-MG, GFR, UAER and incidence of adverse reaction were compared between the two groups before and after treatment.【Results】There was no significant difference in the levels of hs-CRP, SCR and LDL-C between the two groups before treatment (P>0.05). After treatment, the levels of hs-CRP, SCR and LDL-C decreased significantly in the two groups, and the difference was statistically significant (P<0.05). There was no significant difference in UAER, β2-MG and GFR between the two groups before treatment (P>0.05). After treatment, UAER, β2-MG and GFR decreased in both groups (P<0.05). UAER, β2-MG decreased significantly in the observation group (P<0.05). However, there was no significant difference in GFR between the two groups after treatment (P>0.05). The incidence of adverse reactions in the observation group was 19.57% (9/46), which was significantly lower than that in the control group 36.96 % (17/46), the difference was statistically significant (P<0.05).【Conclusion】Valsartan combined with Atovastatin in the treatment of early DN patients can effectively reduce the levels of hs-CRP, SCr and LDL-C, improve renal function and reduce the incidence of adverse reactions, which is worthy of clinical application.
|
|
Received: 13 April 2017
|
|
|
|
|
|
[1] 杨虹.阿托伐他汀联合缬沙坦治疗早期糖尿病肾病的疗效观察[J].医学临床研究,2008,25(5):907-908.
[2] 陶尚成,周秋涛.金水宝治疗早期糖尿病肾病疗效观察[J].医学临床研究,2009,26(7):1271-1272.
[3] 黄萍,李耘.厄贝沙坦对血压正常的老年初期糖尿病肾病患者尿微量白蛋白和超敏C反应蛋白的影响[J].医学临床研究,2011,28(5):956-957.
[4] 李尚娥,方毅,郭庆玲.老年高尿酸血症与糖尿病前期及胰岛素抵抗的相关性研究[J].湖南师范大学学报(医学版),2016,13(5):54-56.
[5] 易建文,徐飞,余启华,等.糖尿病肾病早期实验室检测指标与病程关系的探讨[J].湖南师范大学学报(医学版),2009,6(2):11-13.
[6] Shishehbor MH,Hazen SL.JUPITER to Earth: A statin helps people with normal LDL-C and high hs-CRP,but what does it mean [J] ?Cleve Clin J Med,2009,76(76):37-44.
[7] 陈蕊华,蒋晓真,周龙珠,等.不同糖代谢状态人群血浆可溶性CD36水平及相关因素研究[J].中国全科医学,2014,17(20):2337-2340.
[8] 林文静,张秋霞,胡职舟.缬沙坦联合阿托伐他汀对早期糖尿病肾病患者微量白蛋白尿及血清hs-CRP水平的影响[J].中外医学研究,2017,15(11):134-135. |
|
|
|
2018, Vol. 35 
